Europe’s biggest company, Novo Nordisk, has rebuffed fears of a hit to its business from Donald Trump’s threatened tariffs, as it reported better-than-expected revenues after sales of its weight-loss drug Wegovy almost doubled.

Since taking office, the US president has imposed tariffs on Mexico and Canada – since paused for a month – and China, and has said levies of imports from the EU will “definitely happen”.

Last month, the chief executive of Novo Nordisk, Lars Fruergaard Jørgensen, was one of several Danish company bosses to meet the country’s government to discuss concerns about Trump’s threats to take over Greenland, part of the kingdom of Denmark.

Asked about tariffs at a press conference on Wednesday, Jørgensen said Novo was “not immune, but we are confident our business is in a good position to meet the demands of the new [US] administration”.